Jazz Pharmaceuticals plc
JAZZ
$181.37
-$0.65-0.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.09% | 6.74% | 2.14% | -0.46% | 7.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.09% | 6.74% | 2.14% | -0.46% | 7.53% |
| Cost of Revenue | 24.20% | 15.47% | 5.79% | 12.32% | 21.40% |
| Gross Profit | 8.80% | 5.71% | 1.70% | -1.48% | 6.43% |
| SG&A Expenses | 9.54% | 16.38% | 5.87% | 46.15% | 11.00% |
| Depreciation & Amortization | 6.82% | 6.93% | 4.43% | -0.82% | 4.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.33% | 10.05% | 0.29% | 15.94% | 10.26% |
| Operating Income | 27.73% | -3.34% | 9.79% | -124.74% | -1.49% |
| Income Before Tax | 56.46% | -95.52% | -633.40% | -3,642.05% | 118.13% |
| Income Tax Expenses | 108.57% | -1,568.09% | 43.99% | -252.64% | -75.02% |
| Earnings from Continuing Operations | 6.45% | 16.91% | -526.22% | -533.06% | 102.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.45% | 16.91% | -526.22% | -533.06% | 102.98% |
| EBIT | 27.73% | -3.34% | 9.79% | -124.74% | -1.49% |
| EBITDA | 18.73% | 1.01% | 8.41% | -48.29% | 1.46% |
| EPS Basic | 5.55% | 18.29% | -537.98% | -549.38% | 109.82% |
| Normalized Basic EPS | 42.31% | 2.43% | 26.45% | -329.30% | 3.60% |
| EPS Diluted | 3.21% | 19.28% | -571.31% | -549.38% | 118.51% |
| Normalized Diluted EPS | 39.16% | 3.81% | 40.02% | -329.30% | 13.54% |
| Average Basic Shares Outstanding | 0.86% | -1.17% | -2.68% | -2.49% | -3.26% |
| Average Diluted Shares Outstanding | 3.14% | -2.48% | -12.11% | -2.49% | -11.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |